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and dimerization states could be shown between various 
cortical zones. The results demonstrate a significant change 
in the expression of Nogo-A during the development of the 
human brain. The effects of its time- and region-specific reg-
ulation have to be further studied in detail. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Reticulons are a diverse family of proteins, all contain-
ing a highly conserved reticulon homology domain at the 
carboxy terminus but with highly variable N-terminal
sequences (reviewed by Yang and Strittmatter  [1] ). As a 
member of this protein family, Nogo contains the con-
served domain but it is the unique behavior of the non-
conserved domains that are of most interest to this study. 
Since the discovery of Nogo over a decade ago, it has be-
come clear that it serves a prominent role in neurodevel-
opment as a regrowth inhibitor  [2] . This function has out-
comes relevant to a wide range of disorders, including 
epilepsy, vascular physiology, muscle pathology, stroke, 
inflammation and central nervous system (CNS) tumors.
 Key Words 
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 Abstract 
 Nogo is a member of the reticulon family. Our understanding 
of the physiological functions of the Nogo-A protein has 
grown over the last few years, and this molecule is now rec-
ognized as one of the most important axonal regrowth in-
hibitors present in central nervous system (CNS) myelin. No-
go-A plays other important roles in nervous system develop-
ment, epilepsy, vascular physiology, muscle pathology, 
stroke, inflammation, and CNS tumors. Since the exact role of 
Nogo-A protein in human brain development is still poorly 
understood, we studied its cellular and regional distribution 
by immunohistochemistry in the frontal lobe of 30 human 
fetal brains. Nogo-A was expressed in the following cortical 
zones: ependyma, ventricular zone, subventricular zone, in-
termediate zone, subplate, cortical plate, and marginal zone. 
The number of positive cells decreased significantly with in-
creasing gestational age in the subplate and marginal zone. 
Using different antibodies, changes in isoform expression 
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 Three isoforms of Nogo (Nogo-A, -B and -C) exist 
that arise from a single gene via alternative splicing or 
alternative promoter usage. All of them are members of 
the reticulon family  [3] . Nogo-A is known to be expressed 
by oligodendrocytes and neurons and is present on oli-
godendrocytes in the inner and outer loops of the myelin 
sheath  [3, 4] . Nogo-A has two transmembrane compo-
nents with an intervening 66-amino-acid domain. The 
latter domain is thought to be extracellular, but its exact 
topology has not yet been clarified  [5] . Two domains have 
neurite growth-inhibitory properties, the 66-amino-ac-
id extracellular loop (Nogo-66) and its N-terminal re-
gion (Amino-Nogo). Amino-Nogo requires immobiliza-
tion to a substrate and dimerization for it to be effective 
as a neurite outgrowth inhibitor, but this is not the case 
for Nogo-66, being able to induce growth cone collapse 
in soluble form  [6] . Although the extracellular location 
of Nogo-66 is deemed to enable the inhibitory effects of 
Nogo-A, CNS injury inevitably leads to myelin destruc-
tion and exposure of Amino-Nogo as well. The Nogo re-
ceptor (NgR) mediates the inhibitory action of Nogo-66 
 [6] . The NgR is a glycosylphosphatidylinositol-anchored 
protein that associates with p75 neurotrophin receptor 
 [7] . In addition to inhibition of neurite outgrowth, these 
molecules have other functions. Nogo-A, MAG and 
OMgp are localized at distinct axonal domains and are 
involved in axoglial interactions  [8, 9] .
 In the adult human nervous system, Nogo-A is ex-
pressed predominantly in oligodendrocyte cell bodies 
and myelin sheaths, and to some extent in neurons of the 
brain and spinal cord, especially in most brain stem nu-
clei, dorsal root ganglion sensory cells, and spinal cord 
motor neurons and interneurons  [10] . The presence of No-
go-A in adult neurons suggests that this protein has other 
roles beyond axonal growth inhibition, even in the mature 
CNS. These roles could include attractive or repulsive sig-
naling for other neurons, signal transduction for un-
known ligands, or some other intracellular functions  [11] .
 During brain development, Nogo-A is known to be 
expressed by several neuronal populations and to have a 
role as a growth promoter and a fiber tract forming factor 
 [12–15] . During early stages of myelination, Nogo ap-
pears to have a major impact on the local distribution of 
potassium channels in the paranodal region, through an 
interaction with the Caspr-F3 axoglial complex mediated 
by the Nogo-66 region  [9, 16] . The Caspr-F3 complex is 
responsible for the architecture of the axolemmal-glial 
apparatus. The Nogo-A-Caspr complex directly interacts 
with K v 1.1 and K v 1.2 potassium channels and thereby in-
fluences their segregation to the juxtaparanodal region. 
Consistent with the view that Nogo is not involved in ax-
onal growth at this stage of myelination, Nogo-A, but not 
NgR, localizes to the paranodes, and Nogo-A, Caspr and 
K v 1.1 channels have a similar spatial and temporal rela-
tionship during development. Nogo-A expression by mu-
rine radial glia and postmitotic neurons was recently de-
scribed  [17] . Nogo-A was not restricted to a specific ra-
dial glial population in the developing telencephalon, and 
both radial glia of the dorsal and ventral telencephalon 
expressed the protein  [17] . In the study of Mingorance-Le 
Meur et al.  [17] , Nogo-A was enriched at the leading pro-
cess of tangentially migrating interneurons but not in ra-
dial migrating neurons. At embryonic day (E) 12.5, No-
go-A was detected in radially oriented processes through-
out the cortical lineage. At low levels, Nogo-A was 
demonstrated to appear on the surface of many cortical 
neurons. In  Nogo -deficient background, neurons dis-
played early polarization and increased branching in vi-
tro, probably reflecting a cell-intrinsic role of Nogo pro-
teins in branching reduction  [17] . Early tangential mi-
gration was demonstrated to be delayed in the same 
investigation. The aim of the present study was to exam-
ine the expression of Nogo-A during normal human 
brain development using antibodies directed against an 
epitope within the N-terminal region of Amino-Nogo re-
quired for dimerization [antibody 1 (Ab-1)] and an epi-
tope adjacent to the Nogo-66 region [antibody 2 (Ab-2)]. 
Significant decreases of Nogo-A expression were ob-
served with advanced gestational age (GA).
 Materials and Methods 
 Materials 
 In the present study, tissue from the frontal lobe of 30 human 
fetal brains of various GAs was studied. The demographics of 
each individual as well as clinical data and neuropathological 
changes are listed in  table 1 . After the death of the patient, the 
brain was removed within 24 h and fixed in a 4% formaldehyde 
solution for 1 week. The GA of the fetuses was assessed using the 
gyrification pattern of the brain and compared to clinical infor-
mation. Then, the brain was cut into a series of coronal sections, 
each of which was paraffin embedded. Routine neuropathological 
examination was carried out on sections stained for HE, cresyl 
violet and Luxol fast blue.
 Antibody Generation 
 Polyclonal antibodies were generated to two regions of Nogo-
A. The program Protean (DNaStar) was used to select optimal 
peptide epitopes of 15–20 residues in size.  Figure 1 shows the lo-
cation of the two epitopes for antibody generation (Ab-1 and Ab-
2), the surface probability plot (to optimize the likelihood of epi-
tope being available for the antibody), the coiled-coil regions (ter-
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Case
No.
Clin-
GA
NP-
GA
Gen-
der
Clinical data Neuropathological changes
1 18 16–19 x Amniotic membrane infection syndrome
Severe immaturity 
No neuropathologic changes
2 18 16–19 f Spontaneous birth at 18th gestational week
Hyperemesis in early gestational period
No neuropathologic changes 
3 18 16–19 x No information available Discrete subarachnoid hemorrhage
Cortical verruca formations
Persistence of germinal matrix cells in the 
frontal lobe
4 18 16–19 x Abortus incipiens
Late abortion 18th gestational week
Brain edema
Cortical verruca formations
5 20 16–19 x No information available  Cortical verruca formations
6 20 17–20 x Imminent abortion
Premature abruption of placenta 
Cortical verruca formations
7 17 16–19 x Cytogenetically proven trisomy 21 Hydrocephalus
Accessory lateral ventricle (frontal)
Ectopic aggregation of germinal matrical cells in 
intermediate areas (occipital lobe)
Cortical verruca formations 
8 21 20–23 x Trisomy 21
Late abortion in 21st gestational week
Fresh meningeal hemorrhages
Cortical verruca formations
9 26 20–23 f Placental infarction
Premature abruption
Insertio velamentosa of the umbilical cord 
No neuropathologic changes
10 22 20–23 x Infection with toxoplasma
Oligohydramnios
No neuropathologic changes 
11 21 20–23 f Cytogenetically proven trisomy 21 Germinal matrix hemorrhage
Discrete vernal hemorrhages
Small heterotopia of undifferentiated migrating 
cells
12 24 20–23 f Premature abruption of placenta
Generalized immaturity  
Moderate brain edema
Cortical verruca formations
Persistent matrix cells
Hypoxia 
13 n.a. 20–23 m Trisomy 21
Complete AV channel defect
Right heart failure with pulmonary hypertension
No neuropathologic changes
14  n.a. 23–24 f Preterm birth 23rd gestational week
Intracranial hemorrhage
Hyaline membrane disease
Right heart failure
Hydramnion
Germinal matrix hemorrhage (right side) with  
tamponade of the lateral ventricle, the cerebral 
aqueduct, the IVth ventricle
Discrete circumscribed vernal hemorrhages
15  n.a. 22 f Amniotic membrane infection syndrome
Severe immaturity 
Cortical verruca formations
Moderate brain edema
Persistence of matrical cells (temporal lobe)
16 25 24–27 m Intrauterine hypoxia
Deep placental insertion
Mild subarachnoid hemorrhage
17 24 24–27 x Spontaneous abortion 24th gestational week Cortical verruca formations
Brain edema
Persistence of matrical cells
Hypoxia  
Table 1. D emographic data and neuropathological changes of the examined fetal brains
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tiary structures that, if altered, may affect antibody binding), and 
the phosphorylation sites [the different colors are serine (blue), 
threonine (green) and tyrosine (red), with the solid horizontal 
line indicating threshold significance] ( fig. 1 ). This plot was gen-
erated from NetPhos and the coiled-coil plot from COILS, both 
available on the net.
 Nogo-A Ab-1 was an antibody generated by injecting rabbits 
with a peptide composed of a sequence found near the N-termi-
nus of Nogo-A: EEEEDEDEDLEELEVLERK with a C residue 
added at the carboxy terminus for adjuvant purposes. The region 
selected was without phosphorylation and had a high surface 
probability.
 Nogo-A Ab-2 was an antibody generated by injecting rabbits 
with a peptide composed of a sequence found in a more central 
region of Nogo-A: KVLVKEAEKKLPSDTEKE with a C residue 
added at the carboxy terminus to increase antigenicity. The poly-
clonal antibody generation and ELISA measurements were car-
ried out by GeneMed Synthesis (San Francisco, Calif., USA). The 
ELISA results showed significant peptide-specific reactions at 
sera dilutions of 1: 1 K and 1: 10 K. The region was chosen because 
it contained minimal phosphorylation (hard to find in this pro-
tein) and lacked coiled-coil regions (see B in  fig. 1 ). There is one 
likely phosphorylation site in Ab-2.
Table 1 (continued)
Case
No.
Clin-
GA
NP-
GA
Gen-
der
Clinical data Neuropathological changes
18  n.a. 24–27 m Extreme immaturity
Bronchopulmonary dysplasia
Amniotic membrane infection syndrome
Moderate to severe brain edema
Cortical verruca formations
Persistent matrical cells
Hypoxia
Ventricular hemorrhage
Germinal matrix hemorrhage 
19 27  m Lips-pin-palate column
Clubfoot
Meningoencephalocele
Cortical verruca formations
Band (laminar) heterotopia
20 28 25–30 f Hyaline membrane disease
Intracranial hemorrhage
Hemorrhage
21 29 28–31 f Tumor in left upper arm
Hypovolemic shock
Congestion of vessels
Subarachnoid hemorrhages
22 29  f Infection
Placental insufficiency
Brain edema 
23  n.a. 30 m Hypoplastic left heart insufficiency
Immaturity
No neuropathologic changes 
24  n.a. 32 m Trisomy 13
Lips-pin-palate column
No neuropathologic changes 
25 32 32–35 f Intrauterine death
Placental insufficiency
No neuropathologic changes 
26  n.a. 32–35 m Potter sequence Severe brain edema
Small pontine vascular malformation
Residual matrical cells in the basal ganglia
27  n.a. 32–35 m Potter sequence Moderate brain edema
Disturbed cortical architecture (temporal lobe)
28  n.a. 32–35 x Fetal hydrops
Gender uncertain
Right parietal intracerebral small circumscribed 
hemorrhage
Severe brain edema
Choroidal plexus cyst
Migrational defect (frontal)
29  n.a. 36< f Intrauterine death Congestion of leptomeningeal and 
intraparenchymal vessels
30 39 36< m Intrauterine death Migrational disturbance
Brain edema 
C lin-GA = Gestational age as provided by clinicians; NP-GA = gestational age based on gyrification pattern; x = gender 
uncertain.
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 Validation Antibodies 
 Rabbit anti-Nogo-A (‘Laura’) antibody was used at 1: 1,000. 
Sections were incubated with the secondary anti-rabbit horserad-
ish peroxidase antibody and for visualization of the reaction 
product DAB was used  [18] .
 Antibody Validation by Western Blot Analysis 
 Nogo-A Ab-1 and Nogo-A Ab-2 were tested by Western blot-
ting using fresh-frozen human brain tissue in comparison to the 
well-established ‘Laura’ antibody ( fig.  2 )  [18] . Cortex, i.e. gray 
matter, was compared to white matter. The deep-frozen brain tis-
sues (gray and white matter) were lysed in NP-40 lysis buffer. The 
extracts were centrifuged at 10,000 rpm for 10 min at 4  °  C. Protein 
concentration of each supernatant was analyzed by Bradford as-
say. The protein lysates were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, transferred to polyvinylidene 
difluoride membrane and analyzed by immunoblotting using gel 
electrophoresis (10% gels), transferred to polyvinylidene difluo-
ride membrane and analyzed by immunoblotting using standard 
methods. Membranes were incubated with the following antibod-
ies: anti-Nogo-A Ab-1 (1: 300), anti-Nogo-A Ab-2 (1: 250), rabbit 
anti-Nogo-A (‘Laura’) Ab (1: 20,000; self-made and kindly pro-
vided by Prof. Dr. M.E. Schwab) and anti-GAPDH (1: 5,000; cell 
signaling). As secondary antibody, anti-rabbit-horseradish per-
oxidase (1: 5,000; Amersham) was used.
 Immunohistochemistry 
 Immunohistochemistry was performed on formalin-fixed 
and paraffin-embedded 5-  m-thick sections on Superfrost Plus 
slides (M6146-Plus, Allegiance, McGraw Park, Ill., USA). Depar-
affinized, rehydrated sections underwent antigen retrieval using 
the DAKO target retrieval solution (DakoCytomation, Carpinte-
ria, Calif., USA, No. S1700; equivalent to a 10 mmol/l citrate buf-
fer, pH 6.0) for 20 min in a water bath at 95–100  °  C. All subsequent 
steps were carried out using the DAKO Autostainer Immuno-
staining System (DAKO S3400) and the EnVison TM kit (code 
K4011, DakoCytomation). Sections were treated with 3% H 2 O 2 for 
5 min to block endogenous peroxidase followed by protein block 
(25% casein in PBS containing carrier protein and NaN 2 , DAKO 
code X0909) for 5 min. The primary antibodies were used at con-
probability
of phos-
phorylation
surface
probability
plot
NH2
1.0
0.2
0.4
0.6
0.8
0
0
0 200 400 600 800 1,000
1
COOH
KVLVKEAEKKLPSDTEKEEEEEDEDEDLEELEVLERK
A B
coiled-
coil
regions
 Fig. 1. The location of the two epitopes for antibody generation (A 
and B), the surface probability plot (to optimize the likelihood of 
epitope being available for the antibody), the coiled-coil regions 
(tertiary structures that, if altered, may affect antibody binding), 
and the phosphorylation sites [the different colors are serine 
(blue), threonine (green) and tyrosine (red), with the solid hori-
zontal line indicating threshold significance]. This plot was gen-
erated from NetPhos and the coiled-coil plot from COILS, both 
available on the net. The location of the Amino-Nogo and Nogo-
66 regions are shown on the surface probability plot. For colors, 
see online version. 
C
o
lo
r v
er
si
o
n 
av
ai
la
b
le
 o
n
lin
e
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
16
/2
01
6 
4:
50
:4
5 
PM
 Expression of Nogo-A Is Decreased with 
Increasing Gestational Age  
Dev Neurosci 2012;34:402–416 407
centrations of 1: 300 for Nogo-A Ab-1 and 1: 250 for Nogo-A Ab-2 
for 30 min and 2 h, respectively. Sections were incubated with the 
secondary anti-rabbit antibody (conjugated with horseradish per-
oxidase enzyme-labeled polymer) for 30 min. The reaction prod-
uct was visualized using 3,3  -diaminobenzidine chromogen (liq-
uid DAB+, K3468, DakoCytomation) for 5 min. Then, the sec-
tions were counterstained with Gill 2 hematoxylin (Richard-Allan 
Scientific, Kalamazoo, Mich., USA). As negative control, the pri-
mary antibody was omitted and replaced with normal rabbit se-
rum (code X0903, DakoCytomation).
 Evaluation of the Immunohistochemical Stains 
 On each immunohistochemically stained section, immuno-
positive cells were analyzed separately for each of the following 
topographical locations: ependyma, ventricular zone, subventric-
ular zone, intermediate zone, subplate, cortical plate, and mar-
ginal zone.
 The staining intensity was rated as follows: 0 = no staining,
1 = weak staining, 2 = moderate staining and 3 = strong staining.
 Statistical Analyses 
 The GAs were grouped as follows: GA1 = 16–19 weeks, GA2 = 
20–23 weeks, GA3 = 24–27 weeks, GA4 = 28–31 weeks, GA5 = 
32–35 weeks and GA6 = 36–40 weeks.
 The differences between the GA groups were assessed using 
ANOVA as well as the nonparametric Kruskal-Wallis test (Statis-
tical Package for the Social Sciences, SPSS). Post hoc testing be-
tween the various GA groups was performed using Student’s t 
tests as well as nonparametric Mann-Whitney U test. Correla-
tions were performed using the Spearman rank test.
 Results 
 Both antibodies Ab-1 and Ab-2 were evaluated for 
their ability to detect Nogo-A in human brain tissue. An-
tibody Ab-1 clearly recognized a band at approximately 
50 kDa ( fig. 2 ), corresponding to the molecular weight of 
an isoform of Nogo-A known as Nogo-B  [19] . Nogo-A 
(GenBank: CAB99248.1) and Nogo-B (NP_722550) share 
N-terminal sequences, and thus most antibodies for No-
go-A that are directed towards the N-terminal region also 
recognize Nogo-B.
 In contrast, antibody Ab-2 is directed towards a central 
region that is absent in Nogo-B, and thus Ab-2 is specific 
for Nogo-A (no band corresponding to Nogo-B is seen in 
the Ab-2 results in  fig. 2 ). This was also confirmed by the 
Laura antibody ( fig. 2 c). A BLAST search of the epitope 
recognized by Ab-2 reveals little else in the human pro-
teome that Ab-2 would likely react with. The monomer for 
Nogo-A is 130 kDa but is known to migrate at 180 kDa  [20] , 
and can be seen in lanes 1 and 3 for Ab-2 ( fig. 2 ). Based on 
the Western blot results, it seems that antibody Ab-2 is rec-
ognizing a Nogo-A dimer as the predicted molecular 
weight of the dimer is 260 kDa. Ab-2 is directed towards a 
region free of coiled-coil interactions that lead to dimer 
formation, whereas Ab-1 likely does not recognize this di-
mer because it is directed towards an epitope within the 
a b c
260
160
110
80
60
50
40
30
monomer
monomer
Laura
Nogo-B
55 kDa
dimer
GAPDH GAPDH
GAPDH
40
30
260
kDa kDa kDa
1 2 3 4
Nogo-A Ab-1 Nogo-A Ab-2 Nogo ‘Laura’ Ab
160
110
80
60
50
40
30
40
30
260
160
110
80
60
50
40
40
30
 Fig. 2. Western blot analysis of human cortex compared to white matter.  a Nogo-A Ab-1 (1: 300).  b Nogo-A Ab-2 
(1: 250).  c Nogo-A (‘Laura’) Ab (1: 20,000). 1 and 3 represent white matter, 2 and 4 cortex (30   g protein/lane 
loaded). Nogo-A Ab-2 shows enhanced dimer expression at approximately 260 kDa, while Nogo-A Ab-1 and 
Nogo-A (‘Laura’) Ab do not.  
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coiled-coil region in the N-terminus ( fig. 1 ). When the two 
coiled-coil regions of the respective monomers interact to 
form the dimer, the epitope normally recognized by the 
antibody would be altered and obscured from Ab-1, where-
as the epitope recognized by Ab-2 is still exposed.
 Thus, the top two bands recognized by antibody Ab-2 
are very likely the dimer and the monomer and the ad-
ditional bands observed most probably represent break-
down products  [19] . It is important to note that the dimer 
predominates in white matter (lanes 1 and 3 of  fig. 2 ) but 
is not detected in gray matter (lanes 2 and 4 of  fig. 2 ).
 Using both antibodies, small cells with round nuclei 
corresponding to glial and neuronal cell types could reli-
ably be stained ( fig. 3 ,  4 ). Stained cells were located in the 
ependyma, ventricular zone, subventricular zone, inter-
mediate zone, subplate, cortical plate, and marginal zone.
 There was a significant difference between the two an-
tibodies: the staining intensity was significantly higher 
with Ab-1 compared to Ab-2 ( table 2 ). Based on the dif-
ferences in staining, the subsequent evaluation was car-
ried out by analyzing the results obtained with both an-
tibodies separately.
Periventricular zoneCortex
G
A
 1
6 
w
ee
ks
G
A
 2
4 
w
ee
ks
G
A
 3
7 
w
ee
ks
White matter
Nogo-A Ab-1
 Fig. 3. Representative micrographs of Nogo-A immunopositive cells (stained with Ab-1) of three different age 
categories (GA 16, 24, 37 weeks) in the cortex, white matter and periventricular zone (magnifications indicated 
by scale bars, bar length corresponds to 100   m; insets with higher magnification:  ! 40). For colors, see online 
version. 
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 There was a significant negative correlation between 
Nogo-A Ab-1-positive cells in the subplate and marginal 
zone and GA, as well as between Nogo-A Ab-2-positive 
cells in the marginal zone and GA ( table 3 ). Thus, Nogo-
A immunoreactivities are decreased with increasing GA 
in specific cortical areas.
 For each antibody, the correlation between the various 
locations is shown in  table 4 . For Nogo-A Ab-1 immuno-
reactive cells, the following significant positive correla-
tions were noted: (1) between subplate and subventricular 
as well as intermediate zones, (2) between the cortical 
plate and the ventricular zone, the intermediate zone and 
the subplate, and (3) between the marginal zone and ven-
tricular, subventricular zone, subplate and cortical plate. 
For Nogo-A Ab-2, the positive cells in each region corre-
lated positively with those in all other regions. Thus, in 
each zone, an increase of Nogo-A immunopositive cells 
resulted in an increase in the other zones.
 Results were re-evaluated in a validation set using the 
well-established rabbit anti-Nogo-A (‘Laura’) antibody 
 [18] . By using this antibody, all results found in our pri-
mary study set were reproducible ( fig. 5 ,  6 ).
Periventricular zoneCortex
G
A
 1
6 
w
ee
ks
G
A
 2
4 
w
ee
ks
G
A
 3
7 
w
ee
ks
White matter
Nogo-A Ab-2
 Fig. 4. Representative micrographs of Nogo-A immunopositive cells (stained with Ab-2) of three different age 
categories (GA 16, 24, 37 weeks) in the cortex, white matter and periventricular zone (magnifications indicated 
by scale bars, bar length corresponds to 100   m). For colors, see online version. 
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Table 2. D ifferences in staining between both antibodies for the 
various regions studied
Antibody 1 A ntibody 2 p
mean SEM mean SEM
Ependyma 3.00 0.00 2.46 0.24 0.02
Ventricular zone 2.00 0.21 1.07 0.30 0.03
Subventricular zone 1.40 0.16 0.71 0.22 0.02
Intermediate zone 1.77 0.13 1.33 0.21 0.07
Subplate 1.31 0.12 0.83 0.21 0.01
Cortical plate 1.50 0.16 1.13 0.21 0.08
Marginal zone 2.27 0.11 1.33 0.23 0.00
p values in italics are significant.
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 Fig. 5. Representative micrographs of Nogo-A (‘Laura’) immunopositive cells (stained with Ab-1) of GA 16 
weeks in the cortex and adjacent white matter (magnifications  ! 20,  ! 40,  ! 60 from left to right). For colors, 
see online version. 
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Table 3. C orrelation coefficients (r) and p values between stain-
ing intensities and GA
Antibody 1 A ntibody 2
 r p value r p value 
Ependyma – – 0.21 0.48
Ventricular zone –0.13 0.67 0.07 0.82
Subventricular zone –0.41 0.13 0.20 0.49
Intermediate zone –0.15 0.42 0.15 0.45
Subplate –0.39 0.04 –0.03 0.86
Cortical plate –0.32 0.09 –0.03 0.86
Marginal zone –0.41 0.03 –0.39 0.04
p values in italics are significant.
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 Discussion 
 The extraordinary rapid growth and plasticity of the 
nervous system and the major changes in cell and tissue 
properties occurring during development are due to dif-
ferent protein expression patterns. Nogo-A was first de-
scribed in 2000  [3, 21, 22] . As an axonal regrowth inhibi-
tor, Nogo-A plays an important role in regeneration and 
tissue development although its role in brain develop-
ment remains unclear. Since the discovery of the Nogo 
protein as an individual myelin component capable of 
mediating the inhibition of axonal regeneration, the 
identity of axonal regrowth inhibitors, their physiological 
roles and their mechanisms of action have become partly 
clarified  [23] . Several studies currently aim at blocking 
Nogo-A for therapeutic strategies in order to improve ax-
onal regeneration in spinal cord injury. These targeted 
therapies have already been directed towards blocking in-
teractions between Nogo and its receptor  [24–28] .
 In the present study, Nogo-A was expressed in epen-
dyma, ventricular zone, subventricular zone, intermedi-
ate zone, subplate, cortical plate, and marginal zone. The 
number of immunopositive cells decreased significantly 
with increasing GA in the subplate and marginal zone. 
Nogo-A expression was located in small cells with round 
nuclei resembling glial cells as well as neurons. The data 
we present here illustrate that expression of Nogo-A is 
important during early development. Ab-1 was targeted 
towards the Amino-Nogo epitope and showed a more 
complicated pattern of binding with GA than Ab-2, 
which was targeted to an epitope adjacent to the Nogo-66 
region of the protein.
 As it is the amino terminus that contains the sequence 
that differs between various reticulon genes (reviewed by 
Yang and Strittmatter  [1] ), the data for Ab-1 are more 
likely to represent functions unique to Nogo-A (or its iso-
forms, including Nogo-B) as compared to other proteins 
of the reticulon family. Yet in terms of the isoforms of 
Nogo, it is antibody Ab-1 that is more specific for Nogo-
A. For Ab-1, correlations were observed only between 
some regions with GA, whereas Ab-2 showed consistent 
correlations between regions with GA, i.e. the intensities 
for Nogo-A expression decreased significantly with in-
creasing age. The divergent outcome for Ab-1 and Ab-2 
either reflects different regional patterns of expression of 
Nogo-A versus Nogo-B, or differential dimerization of 
Nogo-A depending on the GA, as the coiled-coil forma-
tion which underlies dimerization at the N-terminus 
would be expected to disrupt the binding of Ab-1 to the 
Amino-Nogo epitope, whereas the binding of Ab-2 to the 
protein would be unaffected by dimerization. While an-
tibody Ab-1 predominantly recognizes a band at approx-
imately 50 kDa corresponding to the molecular weight of 
Nogo-B ( fig. 2 ) as well as a band thought to correspond to 
Table 4. C orrelation coefficients (r) and p values between the various regions for each antibody (Ab) studied
Ventricular 
zone
Subventricular 
zone
Intermediate 
zone
Subplate Cortical plate Marginal zone
r p value r p value r p value r p value r p value r p val ue
Ab-1
Ependyma
Ventricular zone 0.43 0.12 0.39 0.17 0.52 0.06 0.64 0.01 0.57 0.03
Subventricular zone 0.22 0.44 0.61 0.02 0.58 0.02 0.59 0.02
Intermediate zone 0.48 0.01 0.56 0.00 0.32 0.09
Subplate 0.80 0.00 0.56 0.00
Cortical plate 0.66 0.00
Ab-2
Ependyma 0.70 0.01 0.57 0.04 0.86 0.00 0.63 0.02 0.68 0.01 0.70 0.01
Ventricular zone 0.88 0.00 0.88 0.00 0.93 0.00 0.81 0.00 0.68 0.01
Subventricular zone 0.78 0.00 0.94 0.00 0.86 0.00 0.77 0.00
Intermediate zone 0.79 0.00 0.67 0.00 0.55 0.00
Subplate 0.79 0.00 0.78 0.00
Cortical plate 0.79 0.00
p values in italics are significant.
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 Fig. 6. Representative micrographs of Nogo-A (‘Laura’) immunopositive cells (stained with Ab-1) of four dif-
ferent age categories (GA 24, 25, 30, 37 weeks) in the cortex and adjacent white matter (magnifications  ! 20, 
 ! 40,  ! 60 from left to right; insets with higher magnification). For colors, see online version. 
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the monomer of Nogo-A at approximately 180 kDa, anti-
body Ab-2 is recognizing the monomer plus a band at 260 
kDa, the correct size for a dimer of Nogo-A. This dimer 
is predicted to occur through interaction of the coiled-
coil regions in the N-terminus. Because Ab-2 is directed 
towards a region distal from the coiled-coil regions, its 
recognition of the dimer is not impaired. In addition, an-
tibody Ab-2 seems to be more specific than antibody 
Ab-1 as it does not detect the band migrating at the loca-
tion of Nogo-B (approx. 50 kDa).
 Correlation between regions showed that for Ab-2 the 
staining intensity in one compartment paralleled that in 
the other compartments. For Ab-1, however, the staining 
intensity did not correlate between the ventricular zone 
and the subventricular or intermediate zone as well as 
between the subventricular zone and the intermediate 
zone.
 It has become increasingly apparent that Nogo-A 
probably has a variety of roles. Knocking out the gene for 
Nogo or the NgR does not result in a severe phenotype 
under physiological conditions and changes of the regen-
erative capacity of injured CNS. Three independent 
groups reported different and at least partly contradic-
tory results  [29, 30] .
 Among the many clues that  Nogo transcripts might 
have other roles is the growing number of possible inter-
action partners besides the NgR  [30, 31] . Like other mem-
bers of the reticulon family, Nogo is an endoplasmic re-
ticulum-enriched protein, and interactions with other 
endoplasmic reticulum, mitochondrial and cytoplasmic 
proteins may be important for various cellular physiolog-
ical processes. The fact that Nogo-deficient mice appar-
ently exhibit a normal physiological phenotype could be 
related to the compensatory roles that other members of 
the reticulon family might perform in normal physiology 
 [31, 32] .
 As previously shown, Nogo-A expression in adult neu-
rons does not appear to be influenced by the local pres-
ence of inflammatory cytokines or neurotrophic factors 
 [33] . At a cellular level, Nogo-A and NgR are expressed in 
a pattern consistent with their role in axonal-glial inter-
actions and limitation of axonal sprouting in the adult 
CNS  [34] . NgR is expressed in mature neurons, and No-
go-A in the adaxonal myelin sheath and in the outermost 
myelin membranes  [11] . The expression of Nogo-A is not 
significantly altered after CNS injury, unlike other my-
elin molecules. Its role in neurite growth inhibition under 
physiological conditions seems to be restricted to the de-
veloping nervous system, and after that to tonic inhibi-
tion of adult neuronal growth  [11, 35, 36] .
 Nogo-A is known to be highly expressed in oligoden-
drocytes of higher vertebrates, where it localizes mainly 
to the outer and innermost axonal myelin sheath and to 
synaptic sites. During development, oligodendrocytes 
show an expression pattern which directly correlates with 
myelination. In the cerebellum,  Nogo -A mRNA appears 
in oligodendrocytes in deep cerebellar areas at P5 and 
later on, at P9. Nogo-A-expressing neurons are detected 
at the distal ends of the folia in the white matter  [11, 37, 
38] . Although developing neurons express Nogo-A, this 
protein is not expressed in most adult neurons. Olfactory 
receptor neurons as well as cerebellar granular cells show 
high levels of mRNA during development, whereas in 
these cells Nogo-A is downregulated after maturation. 
During development, neurons and glial cells are the ma-
jor source of Nogo-A. Nogo-A seems to be regulated by a 
gradient of positioning and maturation of the cerebral 
cortex  [17] . As its expression is postmitotic, it is first seen 
in the preplate (E11–E12) before the division of this struc-
ture into the subplate and marginal zone, followed by the 
expression of postmitotic cells in the emerging cortical 
plate. In lower vertebrates, which are known to have a 
high regenerative competence, Nogo-A is not found in 
the CNS. This stands in contrast to mammals.
 In mice, tangentially and radially migrating neurons 
display different expression patterns. The genetic abla-
tion of  Nogo leads to a delay in the tangential migration 
of GABAergic interneurons. It was reported that neuro-
nal NgR expression in the neocortex does not start until 
late prenatal and early postnatal stages  [13, 36] . The latter 
finding suggests no functional mediation by NgR at this 
developmental stage, and points to the interaction of 
Nogo with other effectors. Interestingly, the immunohis-
tochemical expression of Nogo-A in ependymal cells has 
not yet been documented in detail.
 Recently, an analysis of Nogo-A mRNA and protein 
expression pattern in the embryonic mouse forebrain was 
performed  [17] . During embryonic development, Nogo-A 
was expressed by radial glia throughout corticogenesis. 
Neuronal Nogo-A protein was expressed in postmigra-
tory cortical neurons, predominantly localized to the 
growing axon. Tangentially migrating GABAergic neu-
rons from the ganglionic eminence expressed Nogo-A, 
targeting the protein to their leading processes.
 Nogo -mutant mice showed no significant changes in 
axonal tracts, although absence of  Nogo resulted in an al-
tered migratory behavior of early GABAergic neurons 
during corticogenesis. Moreover, an increase in axon 
branching and early polarization was described in vitro in 
 Nogo -deficient murine neurons  [39, 40] and preceded 
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NgR expression  [13] . Nogo-A expression was observed to 
be highly expressed in some murine telencephalic axonal 
tracts during early embryonic development  [12, 13, 41] , 
once again indicating that  Nogo- A functions indepen-
dently from NgR at this stage, and likely participates in 
axonal tract formation or neurite growth. The expression 
pattern at perinatal stages of animal CNS development 
has been reported in various studies  [12, 13, 34, 36, 41–43] .
 Nogo mRNA expression was first observed as early as 
E12.5. In the hippocampus, predominantly in the hippo-
campal preplate, Nogo-A was already seen at E12.5. It be-
came enriched in the CA1–CA3 regions by E14.5. More-
over, Nogo-A antibody highlighted cortical afferents and 
efferents such as the corticothalamic and thalamocorti-
cal tracts, the hippocampal fimbria, the corpus callosum, 
the anterior commissure, and the lateral olfactory tract 
 [17] . Nogo-A-positive cells were radially oriented includ-
ing the cortical width at E12.5. Double immunostaining 
of Nogo-A polyclonal antibody and Nestin in the cortex 
of E12.5 and E18.5 mice could be demonstrated to pre-
cisely colocalize in radial glia at E12.5 and partially at 
E18.5, when Nogo-A was still seen at glial end feet. At 
E12.5, Nogo-A was detected in pioneering neurons in the 
preplate contrasting with the nonneuronal Nogo-A ra-
dial glial pattern.
 Other authors have proposed that Nogo probably par-
ticipates in the migration process of early GABAergic 
neurons to the cortex and delays the migration of E12.5-
generated interneurons toward the neocortex. Cortical 
GABAergic interneurons generate from the ganglionic 
eminence and migrate through the intermediate and sub-
ventricular zone before integrating into the cortical plate 
 [44–49] . Between E13.5 and E16.5, a band of tangential 
processes immunoreactive for Nogo-A was seen in the 
lower intermediate and subventricular zone.
 At E14.5, Nogo-A staining was found throughout the 
entire rostrocaudal extent of the telencephalon. Nogo-A 
labeling followed a rostrocaudal gradient in the cerebral 
cortex. Nogo-A protein and mRNA were detected in the 
pyramidal cell layer at E14.5  [14] . During later develop-
ment, at E15.5, Nogo-A immunoreactivity was promi-
nently shown in cortical axonal tracts, in the medial tel-
encephalon and the anterior commissure. At E15.5, No-
go-A protein was absent from the perikaryon of neurons 
located in the lower cortical plate but present in cortico-
fugal axons. At E18.5, Nogo-A was enriched in the corti-
cocortical connections of the corpus callosum, the ante-
rior commissure, and the lateral olfactory tract  [17] . Nogo 
mRNA was also detectable in the cerebral cortex and sub-
cortical regions like the striatum. In the developing cor-
tex,  Nogo mRNA was found in the lower portion of the 
cortical plate (layers VI–V) and the subplate layer VIb 
 [17] . Surprisingly, Nogo-A was expressed by radial glial 
cells from both the ventral and the dorsal telencephalon. 
 Nogo -deficient mice displayed a 25% reduction in the 
number of E12.5-generated interneurons compared with 
control littermates but not in the number of E15-generat-
ed interneurons  [17] .
 Studies by Metin and Godement  [50] demonstrated 
that early generated interneurons (E11–E13) in the me-
dial ganglionic eminence use the corticofugal tract to 
reach the dorsal pallidum by migrating in close contact 
with corticofugal fibers. In another study, a specific de-
crease in the number of early generated interneurons 
(E12.5 cohort) that populate the somatosensory cortex 
was found, possibly indicative of the participation of 
 Nogo in this process  [17] . These data suggest that Nogo-A 
may also regulate tangential migration by acting as an 
adhesion molecule in the corticofugal tract although No-
go-A’s main function is anti-adhesive.
 Nogo-A labeling in growth cones has been shown to 
be restricted to the central region and matched microtu-
bule distribution. Cell culture experiments indicated that 
Nogo proteins are required for appropriate branching 
pattern in cultured neurons and that the absence of these 
proteins leads to early neuronal polarization  [17] .
 Our data from the examination of human brain tis-
sues confirm the reported murine data in a sense that 
significant changes in the expression pattern of Nogo-A 
during early development can be described. As the results 
for Ab-1 and Ab-2 diverge, it is likely that Ab-2 is more 
specific for Nogo-A, whereas Ab-1 recognizes both No-
go-A and Nogo-B. We conclude that Nogo-A plays an im-
portant role in cortical development at various GAs and 
in different brain locations. Dimerization of Nogo-A was 
found to occur only in white matter at one developmental 
time point. Whether this finding holds true across devel-
opmental stages awaits future studies.
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